Why Revelation Biosciences (REVB) Stock Is Down 38%
Why Revelation Biosciences (REVB) Stock Is Down 38%
Revelation Biosciences Inc (NASDAQ:REVB) shares are trading lower by 38% to 58 cents during Tuesday's session after the company said it entered a definitive agreement for the immediate exercise of outstanding warrants to purchase 4,064,040 shares of common stock at $1.00 per share.
Revelation Biosciences Inc（納斯達克股票代碼：REVB）股價在週二的交易中下跌了38％，至58美分，此前該公司表示已達成最終協議，立即行使未償認股權證，以每股1.00美元的價格購買4,064,040股普通股。
The shares, registered under a Form S-3 filing, are expected to generate approximately $4 million in proceeds. The transaction is set to close on December 3, pending customary conditions.
這些股票是根據S-3表格註冊的，預計將產生約400萬美元的收益。根據慣例條件，該交易定於12月3日結束。
Roth Capital Partners is serving as the financial advisor for the deal. REVB shares otherwise gained Monday after the company announced FDA acceptance of Gemini IND.
羅斯資本合夥人擔任該交易的財務顧問。週一，RevB股價也有所上漲，此前該公司宣佈美國食品藥品管理局接受Gemini IND。
Read Also: South Korean ETFs Slide On President's Emergency Martial Law Declaration: 'Protect The Constitutional Democratic Order'
另請閱讀：韓國ETF對總統的緊急戒嚴令宣言下滑：「保護憲法民主秩序」
According to data from Benzinga Pro, REVB has a 52-week high of $25.26 and a 52-week low of $0.51.
根據Benzinga Pro的數據，RevB的52周高點爲25.26美元，52周低點爲0.51美元。